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Dipyridamole increases VP16 growth inhibition, accumulation and
retention in parental and multidrug-resistant CHO cells
RN Turner and NJ Curtin
Cancer Research Unit, Medical School, University ofNewcastle upon Tyne NE2 4HH, UK.
Summary Dipyridamole (DP) has been shown to reverse multidrug resistance (MDR) via interactions with P-
glycoprotein (P-gp). The effect of DP on VP16 growth inhibition was investigated in parental (CHO-KI) and
MDR (CHO-AdrD Chinese hamster ovary cells. CHO-Adrr cells were 18-fold resistant to VP16 and
intracellular accumulation was 28% less than in CHO-Ki cells. DP reduced the resistance of CHO-Adrr to
VP16 by a factor of 2-3 and caused a similar potentiation of VP16 growth inhibition in the parental cells. A
time-dependent increase in intracellular VP16 accumulation, which was similar in both cell lines, was caused by
DP. The intracellular retention of VP16 was increased 2- to 3-fold by DP in both cell lines. The magnitude of
the effect of DP on all three parameters measured was similar (2- to 4-fold), suggesting that the increased
growth inhibition was related to increased intracellular exposure to VP16 owing to the inhibition of the efflux
ofVP16 by DP. However, since the effect of DP was similar in both parental and P-gp-overexpressing cells it is
unlikely that the potentiation of VP16 by DP is mediated via an interaction with P-gp.
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Multidrug resistance (MDR) severely compromises the
efficacy of cancer chemotherapy in the clinic. It occurs when
tumours, which may initially have been sensitive, become
resistant to a variety of anti-cancer drugs. In experimental
models this type of resistance is characterised by reduced
sensitivity to a range of structurally unrelated chemother-
apeutic agents with diverse subcellular targets. This spectrum
of drugs includes many therapeutically important natural
products and their semisynthetic congeners and includes the
anthracyclins, the vinca alkaloids and the epipodophyllotox-
ins. In vitro studies show that MDR is accompanied by
reduced intracellular drug accumulation mediated by
increased drug efflux. Overexpression of a plasma membrane
efflux pump, the p170 glycoprotein (P-gp), the product of the
mdrl gene, has been demonstrated in many cells with the
MDR phenotype and transfection of mdr cDNA can confer
the MDR phenotype through P-gp overexpression (Endicott
and Ling, 1989 and references therein). Inhibitors ofP-gp can
therefore resensitise MDR cells, and many studies have been
conducted into the use of P-gp inhibitors as modulators of
MDR (Wigler and Patterson, 1993).
Dipyridamole (DP), because of its known interaction with
nucleoside transport (Plagemann et al., 1988; Belt et al.,
1993), has been most extensively studied as an augmentor of
antimetabolite cytotoxicity (Schmoll et al., 1990; Goel and
Howell, 1991 and references therein). Nevertheless, several
studies have demonstrated the potentiation of other agents by
DP. Ramu et al. reported in 1984 that DP increased the
cytotoxicity of doxorubicin 15-fold in an MDR subline but
only 2-fold in the parental cell line. Since then several studies
have demonstrated the potentiation of a variety of MDR
drugs by DP (reviewed by Goel and Howell, 1991). There is
good evidence to show that this is mediated via an interaction
of DP with P-gp. DP has been shown to increase the steady-
state intracellular concentration and cytotoxicity of both
vincristine and actinomycin D, and this was associated with
the inhibition of drug efflux, to a far greater extent in MDR
variants than the parental cells (Asoh et al., 1989).
Furthermore, DP inhibited the photoaffinity labelling of P-
gp with [3H]azidopine (Asoh et al., 1989).
The mechanism of the interaction of DP with the cellular
response to VP16 is less clear. VP16 (etoposide), an
epipodophyllotoxin derivative inhibitor of topoisomerase II,
is usually included in the MDR phenotype, although its
transport characteristics and relationship to P-gp are not as
well characterised as the anthracyclins or vinca alkaloids. DP
has been shown to increase the intracellular concentration of
VP16 in both mdr-transfected cells and parental cells but this
was not associated with a synergistic increase in VP16
cytotoxicity (Shalinsky et al., 1990). In other studies DP
enhanced the cytotoxicity, as well as increasing the
intracellular accumulation and decreasing the efflux, of
VP16 in the drug-sensitive 2008 cell line (Howell et al.,
1989a, b). In order to investigate further the role of DP-P-gp
interactions in the potentiation of VP16 cytotoxicity we have
measured the effects of DP on the cellular pharmacology of
VP16 in parental CHO-KI cells and the MDR subline CHO-
Adrr. This cell line was derived by exposure to increasing
concentrations of doxorubicin and has been well charac-
terised (Hoban et al., 1992). It has 5-fold reduced
doxorubicin accumulation, associated with a 4-fold amplifica-
tion of mdrl and elevated P-gp. It is cross-resistant to a
variety of drugs of the MDR family, e.g. actinomycin D but
not non-MDR drugs, e.g. BCNU. The classical MDR
antagonist, verapamil, reversed both doxorubicin and
vincristine resistance in CHO-Adrr cells. CHO-Adrr cells
also have reduced topoisomerase II expression and changes in
some glutathione-S-transferase levels. In contrast to the
reported effects of verapamil on doxorubicin accumulation
and cytotoxicity, strikingly similar effects of DP on VP16
accumulation, efflux and growth inhibition were observed in
both the parental and the MDR cell line.
Materials and methods
Drugs and chemicals
VP16 and DP were obtained from Sigma, Poole, Dorset, UK,
stock solutions were made by dissolving them in dry dimethyl
sulphoxide (DMSO). [3H]VP16 (1.1 Ci mmol-1) in ethanol
was obtained from Moravek Biochemicals, Brea, CA, USA.
Cell lines
Parental CHO-Kl and the P-gp-overexpressing MDR subline
CHO-Adrr (Hoban et al., 1992) were a gift from Dr C
Robson, Department of Surgery, University of Newcastle
upon Tyne. The cell line is reported as stable and it was not
necessary to re-expose CHO-Adrr cells to the selecting agent
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(doxorubicin) during routine culture. The cells were routinely
grown in Hams F-10 (Gibco, Paisley, UK) containing 10%
fetal calf serum (Globepharm, Esher, Surrey, UK) and were
shown to be mycoplasma-free during regular monitoring.
Both mutant and parental cells had a doubling time of 12-
14 h.
Growth inhibition assays
Cells were seeded at 1-1.5 x I03 cells per well in 100 yl of
medium in replicate 96-well plates (leaving the outer wells
with 100 MI of medium alone to minimise 'edge effect') and
allowed to attach overnight. After 16-24 h the medium was
replaced with that containing varying concentrations of VP16
with or without 10 JiM DP in a final DMSO concentration of
0.1%, ten replicate wells were used for each drug
concentration. A replicate plate was fixed as described below
to obtain an estimate of the cell density at the start of the
drug incubation. The plates were incubated for 72 h at 37C
before assaying for cell growth as described previously
(Skehan et al., 1990). Briefly, the 96-well plates were fixed
in ice-cold 10% trichloroacetic acid (TCA) followed by ice-
cold methanol, washed in tap water and air dried. The plates
(together with the preincubation plate) were stained with
0.4% (w/v) sulphorhodamine B (Sigma) in 1% acetic acid
(100 MI per well) for 30 min then rinsed three times in 1%
acetic acid to remove unbound stain. Protein-bound stain was
extracted using 100 MI of 10 mM Tris base (Sigma) per well.
The optical density of the wells was read on a computer-
interfaced MR700 microtitre plate reader (Dynatech, Bill-
ingshurst, West Sussex, UK) relative to an air blank using a
570 nm filter.
Measurement of [3H]VPJ6 accumulation
In order to mimic the conditions for growth inhibition as
closely as possible the accumulation ofVP16 was measured in
complete medium rather than buffer. Cells were harvested
without trypsin, using EDTA in phosphate-buffered saline
(PBS), to avoid the proteolytic digestion ofplasma membrane
proteins. The cells were resuspended at 2 x 107 ml-' in
complete medium with or without 10 gM DP. [3H]VP16 was
added to give a final concentration of 10 jg ml-' (17 gM:
1.1 mCi LM-') andmixedvigorously. The cells were agitated at
room temperature and triplicate 50 yl (i.e. 106 cells) samples
were spun through 100 of silicone oil, specific gravity 1.028
(Dow-Corning 556:550 9:11; BDH, Merck, Lutterworth,
Leicestershire, UK) overlaying 50 ul of 3 M potassium
hydroxide in microfuge tubes (0.4 ml, BDH) at intervals. The
tubes were capped and cut in the silicone layer; the lower
portion, containing the cells lysed in potassium hydroxide, was
placed in scintillation vials. The intracellular 3H was measured,
following neutralisation of the cell lysate with 0.25 M acetic
acid, by scintillation counting on an LKB-Wallac S1410 #-
counter. Viable cell counts (trypan blue exclusion) were taken
at intervals during the accumulation period.
Measurement of [3H]VPJ6 retention
Cells, harvested as described for accumulation experiments,
were resuspended at 2 x 107 ml-' in complete medium
containing 10 Mg ml-' (17 gM) [3H]VP16 (1.1 mCi yM-M)
and agitated for 20 min at room temperature. Triplicate
50 Ml (i.e. 106 cells) samples were spun through oil (as
described above) to determine the initial intracellular VP16
concentration and the remaining cell suspension was pelleted
and resuspended in an equal volume of fresh medium with or
without 10 Mm DP and mixed thoroughly. The cells were
agitated at room temperature and triplicate 50 pl samples
were spun through oil into 3 M potassium hydroxide to lyse
the cells at intervals. The intracellular 3H was measured as
described for the accumulation experiments. Viable cell
counts (trypan blue exclusion) were taken at intervals during
the efflux period.
Results
Growth inhibition assays
The effect of VP16, in the presence or absence of 10 gM DP,
on the growth of parental and MDR CHO cells is shown in
Figure 1. As expected, the CHO-Adrr cells were more
resistant to VP16 than the parental CHO-KI cells. On the
basis of the concentration that inhibits cell growth to 50% of
control growth (IC50) data the CHO-Adrr cells were about 18
times more resistant to VP16 than CHO-Kl cells (Table I).
Co-incubation with 10 uM DP caused a significant increase in
the sensitivity of CHO-Adrr cells but only partially overcame
the resistance to VP16. There was also a significant
enhancement of VP16 growth inhibition by DP in the
parental cells. A comparison of the dose enhancement factor
(DEF50), calculated from the ratio of the IC50 for VP16 in the
absence of DP to the IC50 for VP16 in the presence of DP,
indicated that there was a greater enhancement in the
parental (DEF50 = 4.63+2.75) than the MDR cells (DEF50
= 2.47+0.83), however this difference was not significant.
Intracellular VP16 accumulation
The intracellular accumulation of VP16 was measured in the
two cell lines over 60 min (Figure 2). In the absence of DP,
steady-state concentrations of VP16 were reached within the
first 5 min of incubation in both cell lines. The MDR CHO-
Adrr cells accumulated significantly less VP16 than the wild-
type CHO-KI cells. However, the intracellular VP16
concentration was only 28+5% less in CHO-Adrr cells than
in CHO-KI cells. In the presence of DP, VP16 continued to
accumulate so that steady-state levels had still not been
reached by 60 min. DP effectively increased VP16 content
relative to controls in both cell lines (Table II). This effect
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Figure 1 The effect of VP16 and DP on the growth of CHO-KI
and CHO-Adrr cells. CHO-KI (0, 0) and CHO-Adrr (V, V)
cells were grown in increasing concentrations of VP16 in the
absence (0, V) or presence (0, V) of 10pM DP for 72h before
staining with sulphurhodamine B and measuring the optical
density (OD) at 570 nm. Each point represents the mean and each
vertical bar the s.e.m. of three independent experiments.
Table I Growth inhibition: effect of 10 gM DP on CHO-KI and
CHO-Adrr cells
IC50 gM VPJ6 Fold
CHO-KJ CHO-Adrr resistant
Control 1.39±0.36 24.77+ 5.20 17.82 ±5.94
+ 10 uM DP 0.30+0.16 10.02+2.64
DEF50 4.63 ±2.75 2.47 ±0.83
IC50 values (calculated from a computerised fit ofthe Hill equation)
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Figure 2 The effect of DP on VP16 accumulation in CHO-Ki
and CHO-Adrr cells. Accumulation of [3H]VP16 in CHO-KI (0,
0) and CHO-Adrr (V, V) cells in the absence (0, V) or
presence (0, V) of lOyM DP. Uptake was initiated in cells in
complete medium by the addition of [3H]VP16 (10 gml-1),
samples were taken after 1, 5, 10, 20, 40 and 60min as described
in Materials and methods. Each point represents the mean and
each vertical bar the s.e.m. of three independent experiments.
Table II Effect of 10 gM DP on intracellular VP16 accumulation
Time Intracellular VP16: fold increase by 10 gM DP
(min) CHO-KJ CHO-Adrr
1 1.11 ±0.18 1.44+0.48
5 1.45±0.14 2.02±0.13
10 1.92+0.14 2.37±0.22
20 2.45 ±0.9 3.00±0.35
40 3.26+0.43 3.79±0.42
60 3.38 ±0.37 4.04+0.06
Figures are the mean + s.d. (calculated as the intracellular [VP16] in
the presence of 10 /M DP/the intracellular [VP16] in the absence ofDP
at each time point) from three independent experiments.
was amplified with increasing incubation time so that by
40 min DP had increased the intracellular VP16 concentra-
tion 3.26+0.43-fold in CHO-KI cells and 3.79+0.42-fold in
CHO-Adrr cells. Overall, the effect of DP on the accumula-
tion of VP16 by CHO-Adrr cells did not differ significantly
from that on CHO-Kl cells.
Intracellular retention of VP16
The maintenance of lower steady-state intracellular [VP16] in
the absence of DP than in the presence of DP suggested that
either DP stimulates the uptake of VP16 or that there is an
efflux mechanism operating to limit intracellular accumula-
tion of VP16 that can be inhibited by DP. Therefore the
effect of DP on [3H]VP16 efflux in preloaded CHO-Ki and
CHO-Adrr cells was investigated (Figure 3). The intracellular
VP16 content was 8.3+3 pmol 106 CHO-Kl cells and
7.4+3.9 pmol 106 CHO-Adrr cells before efflux. In the
absence of DP the initial efflux was very rapid in both cell
lines (>50% intracellular VP16 content lost in 1 min).
Thereafter the rate of efflux was slower. DP retarded the
efflux of VP16 in both cell lines, this effect was primarily on
the initial rapid efflux phase. DP had a slightly greater effect
on the CHO-Adrr cells at 1 min, but this was not significant
and thereafter the magnitude of the effect mediated by DP
was remarkably similar in both lines (Table III).
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Figure 3 The effect of DP on VP16 retention in CHO-Kl and
CHO-Adrr cells. Retention of [3H]VP16 in CHO-Ki (0, 0) and
CHO-Adrr (V, V) cells in the absence (0, V) or presence (0,
V) of lOyM DP. Cells were incubated in complete medium
containing [3H]VP16 (10 gml-1), after 20min samples were
taken to determine the initial intracellular VP16 concentration
and the remaining cells resuspended in fresh medium+ ±lOpM DP
with further samples being taken after 1, 5, 10 and 20min as
described in Materials and methods. Each point represents the
mean and each vertical bar the s.e.m. of three independent
experiments.
Table III Effect of 10 /M DP on retention of VP16
Time VP16 retention: fold increase with DP
(min) CHO-K1 CHO-Adrr
1 1.63 ± 0.33 2.09±0.63
5 2.75+1.21 2.70± 1.06
10 2.80± 1.09 2.83± 0.69
20 2.59± 1.09 2.55±0.81
Figures are the mean± s.d. (calculated as the intracellular [VP16] in
thepresence of 10 Mm DP/theintracellular [VP16] in the absenceofDP
at each time point) from three independent experiments.
Discussion
These studies show that the CHO-Adrr cell line is
approximately 18-fold resistant to VP16. However, in drug
accumulation studies the intracellular steady-state level of
VP16 in CHO-Adrr cells was only 28% lower than in CHO-
KI cells, in contrast to the 5-fold reduced doxorubicin
accumulation reported for these cells (Hoban et al., 1992).
This suggests that the resistance to VP16 in CHO-Adrr cells
was mainly due to other mechanisms, probably the 4-fold
reduction in topoisomerase II activity also reported for this
cell line (Hoban et al., 1992).
CHO-Adrr cells have been reported to have a 4-fold
amplification of the mdrl gene and marked P-gp over-
expression that results in a 5-fold increase in doxorubicin
efflux in CHO-Adrr cells compared with the parental cells
(Hoban et al., 1992). However, VP16 retention is not
significantly different in CHO-Adrr from that in CHO-KI
cells after 5 min in drug-free medium (Figure 3). These data
suggest that P-gp plays only a modest role in the efflux of
VP16. Additional evidence suggests that, although VP16 is
recognised by P-gp, it is a poor substrate, for example in a
study of 13 VP16-resistant CHO sublines none overexpressed
P-gp (Soues et al., 1995). Other studies have shown that
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verapamil, an MDR antagonist, does not increase the
retention of VP16 in P-gp-overexpressing Chinese hamster
lung cells (that accumulate 2- to 4-fold less VP16 than the
parental cells) indicating that P-gp was not important in the
efflux of VP16 (Politi et al., 1990). Moreover, VP16 is a poor
inhibitor of the photoaffinity labelling of P-gp by either
azidopine (Sehested et al., 1992) or verapamil (Politi et al.,
1990).
The effect of DP on the efflux of, the accumulation of and
the sensitivity to VP16 was essentially the same in both CHO-
Kl and CHO-Adrr cells. This is in marked contrast to the
effect of verapamil, which has been shown to increase the
accumulation of and sensitivity to doxorubicin to a far
greater extent in CHO-Adrr cells than CHO-Kl cells
(Chatterjee et al., 1990; Hoban et al., 1992). In these studies
verapamil also augmented the accumulation and cytotoxicity
of doxorubicin in the parental CHO-KI cells to a small
extent, presumably owing to the intrinsic moderate expression
of P-gp in wild-type CHO cells (Gupta, 1988). Nevertheless,
if DP was sensitising cells to VP16 via a P-gp mechanism, a
greater effect on CHO-Adrr cells than CHO-Kl cells would
be expected.
DP increased VP16 retention 2- to 3-fold, accumulation 3-
to 4-fold and growth inhibition 2- to 4-fold, i.e. the
magnitude of the effect of DP was similar on all three
parameters. The implication is that the DP-mediated effect on
growth inhibition is due to increased cellular exposure to
VP16, which is related to the reduction in efflux. DP does
appear to be acting via the inhibition of VP16 efflux but to
the same extent in both cell lines. This implies that it is acting
on an efflux mechanism that is not overexpressed in CHO-
Adrr cells compared with the parental cells. Strikingly similar
effects of DP on VP16 accumulation, retention and
cytotoxicity have been reported by Howell et al. (1989b) for
the drug-sensitive human ovarian carcinoma cell line, 2008.
Furthermore these authors demonstrated that the synergy
between DP and VP16 was not due to displacement of VP16
from serum proteins by DP. Similarly, Shalinsky et al. (1990)
observed that DP increased the intracellular steady-state
concentration of VP16 in cells that do not overexpress P-gp
and concluded that DP could potentiate MDR drugs by both
P-gp-dependent and P-gp-independent mechanisms.
The inhibition of VP16 efflux by a mechanism that is not
overexpressed in CHO-Adrr cells (P-gp-independent) could be
due to an effect of DP on the passive diffusion of VP16
across the plasma membrane. However, CHO-Kl and CHO-
Adre cells maintain lower intracellular concentrations of
VP16 in the absence of DP than in its presence (Figure 2)
and DP is known to interact with a variety of plasma
membrane transporter proteins (e.g. nucleoside transporter,
glucose transporter, P-gp). Thus, it is also possible that DP is
inhibiting a VP16 efflux transporter protein that is expressed
to the same extent in both CHO-KI and CHO-Adrr cells.
Recent studies (Soues et al., 1995) using CHO sublines
isolated by resistance to VP16 found that in two highly
resistant sublines there was neither reduced topoisomerase II
nor increased P-gp expression, suggesting the possible
overexpression of another, unidentified, efflux transporter.
Other studies demonstrate that novobiocin can potentiate
VP16 cytotoxicity in non-P-gp-overexpressing multidrug-
resistant cell lines, mediated through the intracellular
accumulation of VP16, but in P-gp-overexpressing cell lines
novobiocin increased neither the intracellular accumulation
nor the cytotoxicity of VP16 (Rappa et al., 1993).
It is now becoming clear that P-gp is not the only plasma
membrane drug efflux protein. At least one other protein, the
multidrug resistance protein, MRP (Cole et al., 1992), also
confers resistance to natural product anti-cancer drugs. There
is evidence to suggest that, whereas VP16 is a poor substrate
for P-gp (Politi et al., 1990; Sehested et al., 1992; Soues et al.,
1995), it is a good substrate for MRP, namely in MCF7 cells
made resistant to VP16 MRP mRNA was increased at least
10-fold (Schneider et al., 1994) and in two HeLa sublines
transfected with MRP the resistance to VP16 (11.6- and 8.9-
fold) was greater than that for most of the other drugs
evaluated (Cole et al., 1994). It is tempting to speculate that
DP augmentation of VP16 in CHO-Ki and CHO-Adrr cells
may be mediated through inhibition of MRP. CHO-KI cells
have a modest overexpression of P-gp (Gupta, 1988) before
selection for drug resistance: it is possible that they might
also express MRP and that this level of expression was not
increased during the selection for resistance to doxorubicin.
However, in a VP16-resistant human ovarian cell line neither
P-gp nor MRP overexpression was detected despite reduced
drug accumulation in these cells (Kubota et al., 1994), which
might indicate the existence ofyet another drug efflux protein
that could be a target for DP. Future studies using an MRP-
overexpressing line will be necessary to address this question.
Abbreviations
MDR, multidrug resistance; DP, dipyridamole; P-gp, P-glycopro-
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